Why Did WonderFi Just Acquire Blockchain Development Firm Blockchain Foundry?

Technology company WonderFi (OTC: WONDF) has announced the acquisition of Blockchain Foundry Inc (BCF), a blockchain development firm.

Technology company WonderFi (OTC:WONDF) has announced the acquisition of Blockchain Foundry Inc (BCF), a blockchain development firm.

BCF, established in 2016, develops and commercializes blockchain-based business solutions focusing on NFT and digital asset infrastructure.

Earlier this year, BCF introduced Metacademy, a “learn-to-earn” educational platform centered on practical Web3 learning, and LastKnown, an NFT minting platform and marketplace for NFTs.

Also Read: Binance To Acquire FTX.com As It Faces ‘Liquidity Crunch’: Here Are The Early Details

BCF’s integration into WonderFi’s Web3 business ecosystem will give their complete product line an immediate boost in scale by connecting them to the company’s 600,000 user base across its Bitbuy and Coinberry platforms, the company said in a statement.

“We are excited to close this transaction and bring the BCF intellectual property in-house,” said WonderFi President and Interim CEO, Dean Skurka.

“We have known this company for a long time and are excited by the prospects of integrating their intellectual property into our core offerings in the near term,” he added.

The company stated that the acquisition will accelerate the growth of full-service Web3 initiatives through improved consumer channels and a larger development ecosystem.
Also, it will provide material consumer and operational synergies across BCF’s complete product suite and development initiatives.

Now read: The FTT Debacle: Want To Cash In? Here’s What Experts Said After Binance Selloff

Total
0
Shares
Related Posts
Read More

AstraZeneca And Merck Announced Results From The Final Analysis Of Overall Survival From Phase 3 Propel Trial Of Lynparza Plus Abiraterone And Prednisone Or Prednisolone (Abi/Pred), Compared To Placebo Plus Abi/Pred. Did Not Reach Statistical Significa…

Median OS was 42.1 months for the LYNPARZA plus abi/pred arm versus 34.7 months for the placebo plus abi/pred arm, representing a 7.4-month absolute difference in median OS versus a standard of care

AZN